Canaccord Genuity Maintains Hold on Vertex Pharmaceuticals, Lowers Price Target to $436

Benzinga Newsdesk www.benzinga.com Negative 80.5%

Neg 80.5% Neu 0% Pos 0%

Canaccord Genuity analyst Whitney Ijem maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and lowers the price target from $437 to $436.